Curasight Overview
- Year Founded
-
2013
- Status
-
Public
- Employees
-
6
- Stock Symbol
-
CURAS
- Investments
-
1
- Share Price
-
$1.10
- (As of Friday Closing)
Curasight General Information
Description
Curasight AS is a clinical-stage radiopharmaceutical company based in Copenhagen, Denmark, developing uTREAT, a first-in-class uPAR-targeted radioligand therapy (RLT) platform designed to treat aggressive solid tumors. The Company is focused on advancing its diagnostic and therapeutic platforms through key clinical milestones.
Contact Information
Website
www.curasight.comCorporate Office
- Ole Maaløes Vej 3
- 2200 Copenhagen
- Denmark
Corporate Office
- Ole Maaløes Vej 3
- 2200 Copenhagen
- Denmark
Curasight Timeline
Curasight Stock Performance
As of 20-Nov-2026, Curasight’s stock price is $1.10. Its current market cap is $54.4M with 49.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.10 | $1.10 | $0.83 - $3.85 | $54.4M | 49.5M | 59.3K | -$0.18 |
Curasight Financials Summary
As of 30-Jun-2026, Curasight has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 154,588 | 81,311 | 24,201 | 48,312 |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (9,439) | (8,276) | (5,737) | (4,662) |
| Net Income | (8,581) | (8,042) | (5,343) | (3,798) |
| Total Assets | 8,568 | 7,872 | 3,305 | 5,752 |
| Total Debt | 0 | 0 | 0 | 0 |
Curasight Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Curasight Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Curasight Signals
Curasight Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Curasight Acquisitions (1)
Curasight’s most recent deal was a Merger/Acquisition with TRT Innovations for . The deal was made on 10-Feb-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| TRT Innovations | 10-Feb-2022 | Merger/Acquisition | Drug Discovery |
Curasight ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Healthcare
Industry
Rank
Percentile
Medical Devices
Subindustry
Rank
Percentile
Curasight FAQs
-
When was Curasight founded?
Curasight was founded in 2013.
-
Where is Curasight headquartered?
Curasight is headquartered in Copenhagen, Denmark.
-
What is the size of Curasight?
Curasight has 6 total employees.
-
What industry is Curasight in?
Curasight’s primary industry is Biotechnology.
-
Is Curasight a private or public company?
Curasight is a Public company.
-
What is Curasight’s stock symbol?
The ticker symbol for Curasight is CURAS.
-
What is the current stock price of Curasight?
As of 20-Nov-2026 the stock price of Curasight is $1.10.
-
What is the current market cap of Curasight?
The current market capitalization of Curasight is $54.4M.
-
What is Curasight’s annual earnings per share (EPS)?
Curasight’s EPS for 12 months was -$0.18.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process